Stock Watch

As confirmed by Mumbai based Sun Pharmaceutical Industries on Thursday, the drug-maker's generic treatment for mental disorders, Strattera has managed to get a tentative approval from the US Food and Drug Administration. Sun's Strattera capsules, as shared by the company in a filing to the Bombay Stock Exchange, are the equivalent of a renowned drug manufacturer Eli Lilly's atomoxetine hydrochloride capsules of the same name, and are currently being offered in 7 strengths of 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg. Recording annual sales of nearly US$ 500 Million in America every year, Strattera is mainly used to treat Attention Deficient Hyperactivity Disorder. Post the announcement of the approval, Sun Pharma's shares gained 0.78% on the BSE to close at a new high of Rs. 1,463.25.